Frazier Life Sciences Management, L.P. Phathom Pharmaceuticals, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.59 Billion
- Q1 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 10,109,279 shares of PHAT stock, worth $98.5 Million. This represents 3.99% of its overall portfolio holdings.
Number of Shares
10,109,279
Previous 10,109,279
-0.0%
Holding current value
$98.5 Million
Previous $82.1 Million
22.78%
% of portfolio
3.99%
Previous 4.92%
Shares
3 transactions
Others Institutions Holding PHAT
# of Institutions
142Shares Held
59.3MCall Options Held
94KPut Options Held
55.5K-
Medicxi Ventures Management (Jersey) LTD7.46MShares$72.7 Million20.28% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$35.6 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$34.1 Million41.56% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$28.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.78MShares$27.1 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $382M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...